info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
A peptide protocol for chronic tendinopathy, ligament laxity, and fibrotic muscle that has not resolved with standard conservative care.
This protocol addresses chronic musculoskeletal conditions, with a focus on tendinopathies, ligamentous laxity, and fibrotic muscle tissue that has not resolved with standard conservative care. It uses a synergistic stack of angiogenic, antifibrotic, and growth-signaling peptides to restart the healing cascade in dormant or "stuck" injuries.
The mechanism moves the tissue environment from a chronic inflammatory or degenerative state (tendinosis) toward active remodeling and collagen synthesis. The protocol is intended for deep tissue repair and is distinct from aesthetic dermal protocols.
This protocol suits patients with chronic musculoskeletal conditions such as lateral epicondylitis, rotator cuff tendinopathy, Achilles tendinosis, or unresolved soft tissue injuries lasting longer than 3 months. The ideal candidate has plateaued with standard conservative therapies (physical therapy, NSAIDs, corticosteroids) and shows evidence of degenerative tissue change rather than acute inflammation.
Candidates must be willing to follow a daily multi-injection schedule. Screen for any history of carpal tunnel syndrome, which growth hormone modulation could worsen.
The foundational agent for soft tissue repair. It upregulates the VEGF receptor to induce angiogenesis, which ensures adequate blood supply to tissues that are typically avascular, such as tendons and ligaments. BPC-157 also helps organize collagen fibers during remodeling to prevent irregular scar formation.
A fragment of thymosin beta-4 that acts on cellular actin to promote cell migration to the injury site. It works with BPC-157 to improve tissue flexibility and reduce intra-articular inflammation. Together, the two downregulate pro-inflammatory cytokines and upregulate anti-inflammatory responses.
A growth hormone releasing hormone (GHRH) analog used here with a drug affinity complex to increase pulsatile release of growth hormone from the pituitary gland. Growth hormone released in response to the normal pulsatile cycle is converted to IGF-1, the primary driver of protein synthesis in connective tissue.
A selective ghrelin receptor agonist that stimulates growth hormone release without significantly raising cortisol or prolactin. Given with CJC-1295, it creates a strong synergistic effect on plasma GH and IGF-1 levels, which anabolic repair needs. When ipamorelin stimulates GH release, the effects of the long-acting GHRH (CJC-1295 with DAC) are amplified through complementary receptors.
Modulates matrix metalloproteinases (MMPs), which helps break down calcification and fibrotic scar tissue in old injuries so new, functional collagen can be laid down. Collagen and elastin are upregulated, which improves outcomes for old injuries.
A peptide that targets the innate repair receptor (IRR). It is indicated mainly for injuries with a neuropathic component, such as nerve entrapment or small fiber neuropathy, to promote nerve regeneration and reduce neurogenic pain.
The amino acid "bricks" (glycine, proline, hydroxyproline) needed to rebuild tendon and ligament. Without enough substrate, peptide signaling for collagen synthesis will be rate-limited.
An obligatory cofactor for the enzymes lysyl hydroxylase and prolyl hydroxylase, which stabilize the collagen triple helix. High-dose supplementation protects the structural integrity of the new tissue.
Needed to balance the administration of copper peptides (GHK-Cu) and to support general enzymatic function in tissue repair.
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 and TB-500 | Subcutaneous | 100 mcg to 600 mcg per 100 lbs of body weight | Daily | Maximum of 12 weeks, followed by a break of at least 4 weeks |
| CJC-1295 with DAC | Subcutaneous | 1 mg | Every 3–4 days | |
| Ipamorelin | Subcutaneous | 200 mcg per 100 lbs of body weight | Up to 3 times per day (typically 2 times per day) | Usually 12 weeks or less |
| GHK-Cu | Subcutaneous | Start at 0.5 mg daily; titrate up by 0.5 mg every 4–7 days as tolerated, to a maximum of 2.0 mg daily | Daily | |
| ARA-290 (conditional) | Subcutaneous | 4 mg | Daily | 28 days, no more than 5 weeks per cycle |
The primary clinical goal is to resolve chronic pain and restore functional range of motion. Patients often report less joint stiffness and less "start-up" pain within the first 14 days. Structurally, the protocol aims to increase the tensile strength of tendons and ligaments, which lowers the risk of re-injury. The systemic rise in IGF-1 also supports muscle hypertrophy and may reverse the atrophy that follows long-term disuse or immobilization.
The CJC-1295/ipamorelin combination can cause transient water retention, which can appear as swelling in the extremities or carpal tunnel-like symptoms. This is a physiological adaptation phase, typically made worse by chronic dehydration and/or excessive salt and electrolyte intake. Advise higher hydration and monitor sodium intake. If it becomes a significant problem and the patient is a good candidate, sauna therapy combined with extra water intake is an acceptable adjunct. Edema is more common in female patients than male patients and typically resolves without further intervention within 3 weeks in men and 6 weeks in women.
GHK-Cu may cause localized pain, redness, or induration after injection, because of its pH and/or an allergic reaction to histidine. Mixing GHK-Cu with PBS (phosphate-buffered saline, pH 7.2–7.4) at a ratio of 2 parts PBS to 1 part GHK-Cu solution immediately before injection reduces the initial reaction caused by the pH difference between the solution and the body. To limit the immune response, use a slow titration schedule and combine the GHK-Cu solution with BPC-157 and TB-500.
Ipamorelin and CJC-1295 can occasionally cause a brief feeling of flushing or lightheadedness right after injection. This is benign and resolves within minutes in most cases. Drinking a glass of water can help.
Patients typically notice less pain between weeks 2 and 3. Functional gains, such as better load tolerance in tendons or a wider range of motion, are expected by weeks 4 to 6. Complete remodeling of chronic fibrotic tissue is slow, so a minimum protocol duration of 8 to 12 weeks is recommended for lasting structural change.
